$SRPT
Sarepta engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. They hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and currently have more than 40 programs in various stages of development. Their vast pipeline is driven by multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing.
I added $SRPT to portfolio, medium term, 3% of the deposit.
stop 76.48 $ = -3%
no take yet
Not an invest recommendation.
